Tumor Reoxygenation Following Administration of the EGFR Inhibitor, Gefitinib, in Experimental Tumors

Karroum, Oussama;Kengen, Julie;Grégoire, Vincent;Gallez, Bernard;Jordan, Bénédicte
(2013) Advances in Experimental Biology — Vol. 789, p. 265-271 (2013)

Files

Karroum2013-b.pdf
  • Open Access
  • Adobe PDF
  • 84.68 KB
Download

Details

Authors
Abstract
It is well recognized that tumor hypoxia is a critical determinant for response to therapy. The effect of an EGFR inhibitor/gefitinib (Iressa®) on tumor oxygenation was monitored daily using in vivo EPR (electron paramagnetic resonance) oximetry on TLT and FSaII tumor models. An increase in pO2 was shown at a dose of 45 mg/kg i.p. (n = 4/group/tumor model). This allowed the identification of a window of reoxygenation in both tumor models (with a maximum between 15 and 20 mmHg after 2 days of treatment). The increase in tumor oxygenation was shown to be the result of a decrease in oxygen consumption. This is the first report on the effect of gefitinib on oxygen consumption by tumor cells and subsequent increase in tumor oxygenation in vivo.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Karroum, O., Kengen, J., Grégoire, V., Gallez, B., & Jordan, B. (2013). Tumor Reoxygenation Following Administration of the EGFR Inhibitor, Gefitinib, in Experimental Tumors. Advances in Experimental Biology, 789, 265-271. https://doi.org/10.1007/978-1-4614-7411-1_36 (Original work published 2013)